Roche to Acquire 454 for $155M, Plans to Use Sequencer for IVD Applications | GenomeWeb
NEW YORK (GenomeWeb News) — Roche Diagnostics today said it plans to acquire 454 Life Sciences from CuraGen for $155 million in cash and stock.
 
Under the deal, Roche will put up $140 million in cash and as much as $14.9 million in outstanding stock options to acquire the subsidiary, which is now seeing early sales of its next-generation sequencers. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.